Skip to main content
. Author manuscript; available in PMC: 2023 May 2.
Published in final edited form as: J Pediatr. 2020 May 28;225:252–258.e1. doi: 10.1016/j.jpeds.2020.05.044

Figure 3.

Figure 3.

Proposed algorithm for evaluation and treatment of liver disease in association with onasemnogene. A, Pregene therapy evaluation for existing chronic liver disease or predisposition to liver disease. B, Post gene therapy monitoring for liver damage and treatment recommendations if liver damage occurs. Ab, antibody; PT, prothrombin time.